Lincoln Pharmaceuticals share news and announcements
NSE: LINCOLNBSE: 531633Pharmaceuticals & BiotechnologySmall Cap
Last close ₹512.70up ₹1.85 (0.36%)BSE ₹514.70
Share price at the NSE close on 23 Oct 2026. Previous close ₹510.85.
52-week range of traded prices to 23 Oct 2026
₹440.00Low, 28 Jan 2026₹770.00High, 27 May 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,027 Cr1,389th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 10.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 28 May 2026
- 1.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.35%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 13.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 11.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 28 May 2026
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 35,18143.1% delivered
Lincoln Pharmaceuticals share news and announcements
352 announcements, routine notices left out, newest first. Page 6 of 8.
Sep 2019
Aug 2019
Jul 2019
1 Jul · Related Party Transactions
May 2019
Apr 2019
3 Apr · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited with respect to announcement dated 28-Mar-2019, regarding " Lincoln Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Darshit Ashvinkumar Shah as Chief Financial Officer of the company w.e.f. March 28, 2019.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment) The response of the Company is awaited.1 Apr · Code of Conduct under SEBI(PIT) Reg., 2015
Mar 2019
28 Mar · Board meeting
19 Mar · Rating
Feb 2019
12 Feb · Board meeting
Nov 2018
14 Nov · Board meeting
Oct 2018
15 Oct · Updates
Sep 2018
Aug 2018
14 Aug · Board meeting
Jun 2018
11 Jun · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited with respect to announcement dated 08-Jun-2018, regarding " Lincoln Pharmaceuticals Limited has informed the Exchange that 'Effective from June 8, 2018, Shri Rajnikant G. Patel [DIN: 00104786] will act as a Non-Executive Director [Promoter Category] of the Company.'.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.
May 2018
Mar 2018
Jan 2018
31 Jan · Board meeting
Dec 2017